Gingivitis Biomarker Segmentation for Personalized Oral Care
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing and treating gingivitis do not effectively differentiate between slow and high responders, leading to inadequate personalized treatment approaches.
Innovation Solution
The development of methods to identify individuals as slow or high gingivitis responders by analyzing variations in host immune reactions and mediator levels, specifically through the quantification of IL-1β, MIF, CCL-1, IL-8, IL-6, and TNFα in gingival crevicular fluid samples.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If standard gingivitis treatment is applied to all patients, then treatment coverage is improved, but treatment efficacy is worsened due to inability to differentiate between slow and high responders
Solution Approach 1:
The patent segments patients into distinct groups (slow responders and high responders) based on their immune response characteristics, specifically IL-1β levels in gingival crevicular fluid. This segmentation allows for tailored treatment approaches where slow responders receive antimicrobial therapy without anti-inflammatory agents, while high responders receive both antimicrobial and anti-inflammatory treatment, thereby improving overall treatment efficacy without excessive complexity
Solution Approach 2:
The patent uses parameter changes by measuring IL-1β levels in gingival crevicular fluid to differentiate between patient types. This biochemical parameter serves as a biomarker that objectively distinguishes slow responders (lower IL-1β levels) from high responders (higher IL-1β levels), enabling personalized treatment selection based on quantifiable immune response parameters
2Reliability
If personalized treatment based on immune response analysis is implemented, then treatment efficacy is improved, but diagnostic complexity is worsened
Solution Approach 1:
The patent introduces IL-1β as an intermediary biomarker that mediates the connection between patient immune response characteristics and treatment selection. By measuring this specific immune mediator in gingival crevicular fluid, the complex immune response is simplified into a measurable parameter that guides treatment decisions, making personalized medicine more accessible
Solution Approach 2:
The patent replaces complex clinical assessment of immune response with a biochemical measurement system. Instead of relying on subjective clinical evaluation of inflammation signs, the invention uses objective quantification of IL-1β levels in gingival crevicular fluid, substituting mechanical/clinical assessment with biochemical analysis for more accurate patient classification
Data Source
AI summary
Methods of identifying an individual as being a slow gingivitis responder or a high gingivitis responder are disclosed. Some methods are based on IL-1β levels in the individual's GCF at the site of inflammation. Some methods are based on MIF and/or CCL-1 levels in the individual's GCF in healthy tissue distant from the site of inflammation. Some disclosed methods are based on temporal differences in IL-8, IL-6 and/or TNFα levels in the individual's GCF in healthy tissue distant from the site of inflammation during the development of plaque induced inflammation. Methods of treating an individual who has gingivitis and methods of preventing gingivitis are also provided. The treatment and prevention methods comprise determining if individual is a slow gingivitis responder or a high gingivitis responder and applying oral care compositions to the individual's oral cavity.